InsiderClue
← All stocks

BridgeBio Pharma, Inc.

BBIO Net selling
CIK 0001743881 #743 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$122.05M
$78.11M on a plan · $37.62M straight out of an exercise
Sold at will
$6.32M
4 of 163 sales
Net
−$122.05M
−$6.32M against sales at will

By person

19 insiders · 163 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Kumar Neil
Chief Executive Officer
—
$60.85M (118) scheduled
−$60.85M
749,013
0.3832%
$64.15M
−71.1%
Cook Jennifer E.
Director
—
$21.92M (6) scheduled
−$21.92M
8,383
0.0043%
$718.00K
+17.2%
MCCORMICK FRANK
Director
—
$13.31M (6) scheduled
−$13.31M
690,558
0.3532%
$59.15M
−32.5%
Lo Andrew
Director
—
$6.32M (4)
−$6.32M
68,662
0.0351%
$5.88M
−72.9%
Ellis Andrea
Director
—
$5.65M (2) scheduled
−$5.65M
22,579
0.0116%
$1.93M
+88.2%
Valantine Hannah
Director
—
$4.37M (6) scheduled
−$4.37M
9,657
0.0049%
$827.12K
+61.5%
DANIELS RONALD J
Director
—
$3.89M (1) scheduled
−$3.89M
20,981
0.0107%
$1.80M
+101.7%
Trimarchi Thomas
President and CFO
—
$3.03M (6) scheduled
−$3.03M
336,529
0.1721%
$28.82M
−15.0%
Scott Randal W.
Director
—
$2.09M (9) scheduled
−$2.09M
11,589
0.0059%
$992.60K
+131.8%
Apuli Maricel
Chief Accounting Officer
—
$621.70K (5) scheduled
−$621.70K
122,687
0.0628%
$10.51M
−2.3%
VIKING GLOBAL INVESTORS LP entity
10% owner
—
—
—
18,555,375
9.49%
$1.59B
−26.1%
KKR Genetic Disorder L.P.
10% owner
—
—
—
13,260,971
6.78%
$1.14B
−47.5%
HOMCY CHARLES J
Director
—
—
—
919,876
0.4706%
$78.79M
−25.2%
Satvat Ali J.
Director
—
—
—
169,983
0.0870%
$14.56M
—
STEPHENSON BRIAN C
CFO and Treasurer
—
—
—
102,464
0.0524%
$8.78M
+20.1%
Hassan Fred
Director
—
—
—
29,879
0.0153%
$2.56M
+54.8%
MOMTAZEE JAMES C
Director
—
—
—
19,070
0.0098%
$1.63M
+124.6%
Dachille Douglas A.
Director
—
—
—
10,579
0.0054%
$906.09K
—
AGUIAR ERIC
Director
—
—
—
10,579
0.0054%
$906.09K
—

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 62
Amendments (4/A) skipped 0
Filings about a different issuer 1
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 137
Sales straight out of an exercise 22
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 1,246,438
History held since 26 Jun 2018